IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

Cited by (221)

Items 201–221 of 221

1. Caracterização de PIMREG como biomarcador em gliomas
   Isabela Spido Dias · 2023
2. The effect of genetics and biochemistry on the pathogenesis of cholangiocarcinoma
   Mete Tuğcan Üçdal, Ayşe Buruş, Başak Çeltikçi · 2024 · International Journal of Hepatobiliary and Pancreatic Diseases
3. Spectrum of Findings Seen in Patients With IDH1/2-Mutant Cholangiocarcinoma
   Andrea Siobhan Kierans, Areeb Lutfi, Maaz Khan Afghan, Sahrish Khan, Sana Javaid, Brian Michael Currie, Juan Pablo Rocca, Benjamin Samstein, Encouse B. Golden, E Popa et al. · 2024 · International Journal of Surgical Pathology
4. Genetic, epigenetic and exosomal biomarkers in neurological malignancies
   Md Tanjim Alam, Jalaj Gupta, Amit K. Srivastava, Prem Prakash Tripathi · 2024 · Elsevier eBooks
5. Presence of Fragmented Intratumoral Thrombosed Microvasculature in the Necrotic and Peri‐Necrotic Regions on SWI Differentiates IDH Wild‐Type Glioblastoma From IDH Mutant Grade 4 Astrocytoma
   Virendra Kumar Yadav, Shalini Sharma, Satyajit Maurya, Rakesh Kumar Singh, Jitender S. Saini, Preeti Jain, Rana Patir, Sunita Ahlawat, Sumanta Das, Sandeep Vaishya et al. · 2025 · Journal of Magnetic Resonance Imaging
6. Additional file 1 of A proteomic profile of the healthy human placenta
   Samprikta Manna, Scheel, Julia, Aisling Noone, Colm J. McElwain, Caitríona Scaife, Shailendra K. Gupta, English, Jane, Cathal McCarthy, Fergus P. McCarthy · 2023 · Figshare
7. Additional file 2 of A proteomic profile of the healthy human placenta
   Samprikta Manna, Scheel, Julia, Aisling Noone, Colm J. McElwain, Caitríona Scaife, Shailendra K. Gupta, English, Jane, Cathal McCarthy, Fergus P. McCarthy · 2023 · Figshare
8. Additional file 1 of Identification of four metabolic subtypes and key prognostic markers in lung adenocarcinoma based on glycolytic and glutaminolytic pathways
   Zhang, Jinjin, Wang, Xiaopeng, Song, Congkuan, Li, Qi · 2023 · Figshare
9. Targeted therapy for acute myeloid leukemia: ivosidenib in patients with IDH1 mutations
   Jan Novák · 2026 · Onkologie
10. Insight into the metabolism of gliomas by MRI and MRS
    Samishtha Pandey, Neha Yadav, Vivek Tiwari, Naranamangalam Raghunathan Jagannathan · 2026 · Biophysical Reviews
11. Génomique intégrée des neuroblastomes olfactifs : implications anatomopathologiques et thérapeutiques
    Marion Classe · 2017 · theses.fr (ABES)
12. Mécanismes et implications thérapeutiques de l'hypermutation dans les gliomes
    Mehdi Touat · 2020 · theses.fr (ABES)
13. Clinicopathologic features of KRAS G12C-mutated non-small cell lung carcinomas:insights from 279 retrospective cases
    Martina Bradová, Petr Slavík, Tomáš Vaněček, Petr Martínek, Petr Grossmann, Stanislav Kormunda, Kristyna Behenska, Martin Svatoň, Miloš Pešek, Tomáš Jirásek et al. · 2026 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
14. Increased glioblastoma risk in patients with myeloproliferative neoplasms and myelodysplastic syndromes
    Huaiyu Zhou, Shenghui Jin, Lei Huang, Wei Liu · 2026 · Clinical and Experimental Medicine
15. Mutational and genomic landscape of acute myeloid leukemia: Insights from a South Asian targeted next-generation sequencing cohort
    Amrit Kaur Kaler, Sameer A. Tulpule, Santanu Sen, Nishant Jindal, Manali Ajagekar, Isha Rajwade, Vatsal Kothari, Kunal Goyal · 2026 · Journal of Hematology and Allied Sciences
16. Sex-based differences in disease-specific survival among patients with chondrosarcoma: A population-based cohort study
    Gabriel Hanna, Michael M. Abdou, Brian Pae, Robert Kamil, Kyle E. Walker, E Bryk, Derek Hansen · 2026 · Cancer Epidemiology
17. Molecular landscape of chondrosarcoma: From tumor biology to therapeutic vulnerabilities
    Elisa Belluzzi, Assunta Pozzuoli, Giulia Trovarelli, Andrea Angelini, Pietro Ruggieri · 2026 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
18. Pharmacoepigenetics: from epigenetic regulation to personalized therapeutics
    Ashley M. Nguyen, Tamer E. Fandy · 2026 · Frontiers in Pharmacology
19. BindingDB Entry 50020328: Structure-Based Drug Design of Novel Triaminotriazine Derivatives as Orally Bioavailable IDH2
    BindingDB · 2024 · UC San Diego
20. BindingDB Entry 50020000: Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors.
    BindingDB · 2024 · UC San Diego
21. BindingDB Entry 50002460: Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.
    BindingDB · 2020 · UC San Diego